|
業務類別
|
Biotechnology |
|
業務概覽
|
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
| 公司地址
| One Design Center Place, Suite 17-500, Boston, MA, USA, 02210 |
| 電話號碼
| +1 857 520-9158 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.entradatx.com |
| 員工數量
| 152 |
| Mr. Dipal Doshi |
Chief Executive Officer and Director |
美元 635.00K |
24/04/2026 |
| Mr. Kory J. Wentworth |
Chief Financial Officer and Principal Accounting Officer |
-- |
24/04/2026 |
| Mr. Nathan J. Dowden |
Chief Operating Officer and President |
美元 499.20K |
24/04/2026 |
| Dr. Natarajan Sethuraman, PhD |
President, Research and Development |
美元 520.00K |
24/04/2026 |
|
|
| Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D. |
Independent Director |
24/04/2026 |
| Dr. Peter S. Kim, PhD |
Director |
24/04/2026 |
| Mr. Dipal Doshi |
Chief Executive Officer and Director |
24/04/2026 |
| Ms. Mary T. Thistle |
Independent Director |
24/04/2026 |
| Dr. Kush M. Parmar, M.D.,PhD |
Chairman of the Board |
24/04/2026 |
| Dr. Mahalakshmi Radhakrishnan, M.D. |
Independent Director |
24/04/2026 |
| Ms. Gina Chapman |
Independent Director |
24/04/2026 |
|
|
|
|
